Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8008 and BAT1308 in Advanced Solid Tumors
NCT06341114Phase 2Active, not recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAT8008 and BAT1308 in solid tumor (6 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 21 days, Vital signs at 1 year and 9 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
BAT8008BAT1308
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06341114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341114.